Parity and Kidney Cancer Risk: Evidence from Epidemiologic Studies
Parity and Kidney Cancer Risk: Evidence from Epidemiologic Studies
复制标题
DOI：
10.1158/1055-9965.epi-13-0759-t
复制
发表时间：
2013-12-01
影响因子：
3.8
通讯作者：
Gong, Ting-Ting
中科院分区：
文献类型：
--
作者：
Guan, Hong-Bo;Wu, Qi-Jun;Gong, Ting-Ting
背景：观察性研究报告了胎次与肾癌风险之间相互矛盾的结果。据我们所知，尚未有关于胎次与肾癌之间关系的全面定量评估报告。因此，我们对已发表的流行病学研究进行了系统回顾和剂量反应荟萃分析，以总结这种关联的证据。方法：通过MEDLINE （PubMed）数据库检索2013年6月底发表的胎次和肾癌相关研究。两位作者独立评估合格性并提取数据。6项前瞻性研究和8项病例对照研究报告了肾癌的相对风险（RR）估计值和95%置信区间（CI）与胎次或胎次数相关。使用固定或随机效应模型来估计总相对风险。结果：胎次与未产的肾癌总相对危险度为1.23 （95% CI, 1.10-1.36; Q = 12.41; P = 0.413; I-2 = 3.3%）。此外，最高胎次数与最低胎次数之间也存在显著关联，总RR = 1.36 （95% CI, 1.19-1.56; Q = 8.24; P = 0.766; I-2 = 0%）。在剂量-反应分析中，每一个活产的相对风险汇总为1.08 (95% CI: 1.05-1.10; Q = 9.34; P = 0.500; I-2 = 0%)，也表明胎次对肾癌风险有积极影响。meta回归分析未发现亚组间存在发表偏倚和显著异质性的证据。结论：总之，本荟萃分析的结果表明，任何胎次和更高的胎次与肾癌风险增加显著相关。影响：目前的结果表明胎次与肾癌风险呈正相关。(c) 2013年aacr。
Background: Observational studies have reported conflicting results between parity and kidney cancer risk. To our knowledge, a comprehensive and quantitative assessment of the association between parity and kidney cancer has not been reported. Thus, we conducted a systematic review and dose-response meta-analysis of published epidemiologic studies to summarize the evidence of this association.Methods: Relevant published studies of parity and kidney cancer were identified using MEDLINE (PubMed) database through end of June 2013. Two authors independently assessed eligibility and extracted data. Six prospective and eight case-control studies reported relative risk (RR) estimates and 95% confidence intervals (CI) of kidney cancer associated with parity or parity number. Fixed-or random-effects models were used to estimate summary relative risk.Results: The summary relative risk of kidney cancer for the parity versus nulliparous was 1.23 (95% CI, 1.10-1.36; Q = 12.41; P = 0.413; I-2 = 3.3%). In addition, significant association was also found for the highest versus lowest parity number, with summary RR = 1.36 (95% CI, 1.19-1.56; Q = 8.24; P = 0.766; I-2 = 0%). In the dose-response analysis, the summary per one live birth relative risk was 1.08 (95% CI: 1.05-1.10; Q = 9.34; P = 0.500; I-2 = 0%), also indicating the positive effect of parity on kidney cancer risk. No evidence of publication bias and significant heterogeneity between subgroups was detected by meta-regression analyses.Conclusions: In summary, findings from this meta-analysis suggest that ever parity and higher parity number is significantly associated with increased risk of kidney cancer.Impact: The present results suggest a positive association between parity and kidney cancer risk. (C) 2013 AACR.